Browse by author
Lookup NU author(s): Professor John IsaacsORCiD
Introduction: Our objective was to determine the interrelationships of interleukin (IL)-6 receptor inhibition with haemoglobin, acute-phase reactants and iron metabolism markers (including hepcidin) in patients with rheumatoid arthritis (RA). Methods: Data of patients receiving tocilizumab or placebo in the MEASURE study were analysed. We investigated associations at baseline and during tocilizumab treatment among haemoglobin, parameters of haemoglobin and iron homeostasis [ferritin, total iron-binding capacity (TIBC), hepcidin, haptoglobin], IL-6 and acute-phase reactants [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)] to identify statistical correlates of rise in haemoglobin level. Results: At baseline, CRP and haptoglobin were inversely correlated (modestly) with haemoglobin levels. After treatment with tocilizumab, CRP, hepcidin, ferritin and haptoglobin levels fell alongside increases in TIBC and haemoglobin. The falls in CRP, hepcidin and haptoglobin levels in the first 2 weeks correlated with a week 12 rise in TIBC and haemoglobin. Conclusions: Inflammatory anaemia improves in patients with RA treated with tocilizumab. This improvement correlates with the degree of suppression of systemic inflammation, reduction in hepcidin and haptoglobin and increase in iron-binding capacity. These clinical data provide evidence of a role for IL-6 signalling in the inflammatory anaemia of RA.
Author(s): Isaacs JD, Harari O, Kobold U, Lee JS, Bernasconi C
Publication type: Article
Publication status: Published
Journal: Arthritis Research & Therapy
Year: 2013
Volume: 15
Issue: 6
Print publication date: 02/12/2013
Date deposited: 02/05/2014
ISSN (print): 1478-6354
ISSN (electronic): 1478-6362
Publisher: BioMed Central Ltd
URL: http://dx.doi.org/10.1186/ar4397
DOI: 10.1186/ar4397
Altmetrics provided by Altmetric
